AbbVie and Gilgamesh Pharmaceuticals | Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric Disorders

Under terms of the agreement, AbbVie and Gilgamesh Pharmaceuticals have agreed to research and develop a portfolio of next-generation therapeutics for psychiatric disorders.

← Previous
Next →
  • HEALTH / LIFESTYLE
  • ARTICLES OF INTEREST
  • ABOUT
    • EDITORIAL
    • SUBMIT PRESS RELEASES
  • ADVERTISE
  • CONTACT
  • PRIVACY
    • COOKIE POLICY
  • HEALTH / LIFESTYLE
  • ARTICLES OF INTEREST
  • ABOUT
    • EDITORIAL
    • SUBMIT PRESS RELEASES
  • ADVERTISE
  • CONTACT
  • PRIVACY
    • COOKIE POLICY

© 2026 All rights Reserved. Medical Device News Magazine, is a Division of PTM Healthcare Marketing, Inc.